Inhibikase Therapeutics, Inc. Segments Disclosure
17. Segment Information
The Company views its operations and manages its business as one operating and reportable segment, which is the business of developing protein kinase inhibitor therapeutics. Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (“CODM”), manages and allocates resources on a consolidated basis using consolidated net income (loss) as a measure of profit/loss for the single reportable segment. This decision making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.
|
Year ended December 31, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Costs and expenses: |
|
|
|
|
|
||
Research and development (excluding stock-based compensation) expense: |
|
|
|
|
|
||
PAH(1) |
$ |
22,453,185 |
|
|
$ |
1,672,869 |
|
Parkinson's disease |
|
647,242 |
|
|
|
9,333,359 |
|
Other research and development |
|
1,219,560 |
|
|
|
1,512,151 |
|
Selling, general and administrative (excluding stock-based compensation) |
|
13,718,314 |
|
|
|
7,930,072 |
|
Change in fair value contingent consideration |
|
(1,373,942 |
) |
|
|
- |
|
Stock-based compensation expense |
|
15,309,924 |
|
|
|
8,140,617 |
|
Total costs and expenses |
|
51,974,283 |
|
|
|
28,589,068 |
|
Loss from operations |
|
(51,974,283 |
) |
|
|
(28,589,068 |
) |
Interest income |
|
3,715,094 |
|
|
|
1,069,182 |
|
Net loss |
$ |
(48,259,189 |
) |
|
$ |
(27,519,886 |
) |
(1) This amount includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition during the year ended December 31, 2025.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 26, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.